- Review Article
- Open Access
Verisimilitude (or “truthlikeness”) as an alternative to pro and cons: migraine and cluster headache mechanisms
The Journal of Headache and Painvolume 11, pages379–389 (2010)
Calculating verisimilitude (or “truthlikeness”) ad modum Popper is a quantitative alternative to the usual pros and cons in migraine and cluster headache mechanisms. The following items were evaluated: dilation of large cranial arteries during migraine; CGRP increase during migraine; migraine as a brain disorder; aura and migraine headache; brain stem activation during migraine; rCBF in migraine without aura; NO and pathophysiology of migraine; neurogenic inflammation and migraine; aura in cluster headache; and hypothalamic activation in cluster headache. It is concluded that verisimilitude calculations can be helpful when judging pathophysiological problems in migraine and cluster headache.
What Hume called our ‘natural instincts’ are stronger than any philosophical argument. In my view this applies to science as well.
Peter Lipton, 2005 .
Pathophysiological studies of migraine often involve new techniques to reveal abnormalities compared with a control group. Alternatively, an intervention provokes a migraine attack [2–5], with patients assessed before and after the intervention. Migraine research is increasingly hypothesis driven as migraine mechanisms become better understood [6, 7].
Philosopher of science Sir Karl Popper stated, “a good theory…makes a number of predictions that can in principle be disproved or falsified by observation” . Established methods for comparing drug effects  include designing randomized clinical trials based on the null hypothesis. Additionally, systematic reviews or meta-analyses can estimate effects within 95% confidence intervals (CI) [10–13]. Systematic meta-analyses are not applicable to migraine mechanism theories and differing results with different methodologies prevent direct comparisons. To deal with such situations, Popper introduced the concept of verisimilitude (or “truthlikeness”)  to score the degree of likelihood of truth in a theory or statement. The concept has advantages over the pros and cons that are normally used where there are disagreements, as often occur in headache research. We applied the concept to several important migraine and cluster headache mechanisms. This exercise is aimed toward enlightening the migraine research field and to indicate where further research is needed.
Verisimilitude (or “truthlikeness”) of a theory a can be expressed ad modum Popper  as:
where Vs(a) is the verisimilitude of a, CTv(a) is a measure of the truth content of a, and CTf(a) is a measure of the falsity of a .
When calculating Vs(a) in Table 1, both CTv(a) and CTf(a) were given arbitrary values of 0, 0.25, 0.5, 0.75, or 1.0 for simplicity. The results for verisimilitude, Vs(a), can thus be −1.0 (very unlikely), −0.75 (most unlikely), −0.5 (unlikely), −0.25 (probably unlikely), 0 (undecided), +0.25 (probably likely), +0.5 (likely), +0.75 (most likely), or +1.0 (very likely).
To exemplify, we chose both easy problems and problems requiring extensive comments and where the result of the analyses remains open for discussion. Our judgment of the evidence, indicated as CTv(a) and CTf(a), is given in Table 1 together with the calculated Vs(a).
Results and comments
Does dilation of larger cranial arteries cause the pain in migraine headache?
Extracranial arterial vasodilation is traditionally regarded as the cause of migraine headache [15, 16]. Increased temporal pulsations were observed during migraine, and these pulsations decreased after intravenous ergotamine in parallel with the effect on headache . Decreased blood velocity in the middle cerebral artery (MCA) during migraine, measured with transcranial Doppler (TCD), was found . Since the cerebral blood flow was unchanged, it indicated dilation of the MCA . This finding was confirmed with TCD in two small studies in 25  and 10  patients, respectively. The CTv(a) is 1.0.
In two relatively large studies with 31  and 51  patients, respectively, no decrease in blood flow velocity was found with TCD during migraine attacks. Furthermore, a recent magnetic resonance angiography (MRA) study found no MCA or extracranial part of the middle meningeal artery (MMA) dilatation during nitroglycerin-induced migraine (n = 20) . Arguably, a negative study could theoretically be caused by variability in measurements, but in the MRA study , MMA (17%) and MCA (11%) vasodilation was observed during the 20-min infusion of nitroglycerin. We judge the CTf(a) to be 1.0. The verdict is still out concerning large cranial artery vasodilatation during migraine and the verisimilitude is 0.
Is calcitonin gene-related peptide (CGRP) increased in the external jugular vein (EJV) during migraine attacks?
For many years it has been known that CGRP is increased in the EJV blood during migraine attacks [23, 24] leading to the conclusion that CGRP is a neuropeptide elevated during migraine attacks . In a study of very long-standing attacks (median 11 h), sumatriptan treatment normalized CGRP levels . The CTv(a) is 1.0.
Calcitonin gene-related peptide (CGRP) was unchanged in two spontaneous migraine studies [26, 27]. Both the studies used intra-patient design [26, 27]. In one study , two CGRP analyses methods were used including a method used previously by Goadsby et al. [23, 24], but no change in CGRP was observed. Furthermore, in one nitroglycerin-induced migraine attack study, CGRP was not increased . The CTf(a) is 1.0. Currently, there is similar evidence for and against increased CGRP in the EJV, and the verisimilitude is 0.
Is migraine a dysfunction of the sensory modulatory network?
Most neurologists agree that migraine starts in the brain and confer the prodromes and aura, but their opinions about the headache phase differ. Recently, a proponent of pure CNS pathophysiology stated, “Migraine is a dysfunction of the sensory modulatory network with the dominant disturbance affecting abnormal processing of essentially normal neuronal traffic” .
The prodromes that occur in 30% of patients  and auras that occur in 20% of patients  must originate in the CNS. During aura, there is a characteristic spreading oligemia in the cerebral cortex [30–32]. Other evidence for CNS involvement during migraine attacks is available. Persistent brain stem activation was observed by PET during migraine attack [4, 33, 34]. Additionally, hypothalamic activation is observed during migraine attacks . Few cases of symptomatic migraine caused by brain stem lesions are reported [35, 36]. Other migraine symptoms, such as photo- and phonophobia, are without peripheral cause . β-blockers used as migraine prophylactics probably exert their effect in the CNS . Valproate and topiramate also probably work in the CNS . In rats, chronically administered prophylactic migraine drugs like propranolol, valproate, topiramate amitriptyline, and methysergide suppressed CSD frequency and increased the cathodal stimulation threshold required to evoke CSD .
Additionally, 5-HT1B/1D receptors are present in the brain stem , which could explain the efficacy of triptans and alkaloids in migraine. There are many pros and the CTv(a) is 1.0.
In an animal model of migraine, c-fos expression and the “evoked potential” are observed in the trigeminal nucleus caudalis (TNC) after superior sagittal sinus stimulation in the cat [40–43]. There appears to be a peripheral source for this “brain stem” activity in the animal migraine model. CSD activates trigeminal afferents, resulting in a series of cortical, meningeal, and brain stem events consistent with the development of a process similar to headache pain transmitted by the trigeminal nerve in this animal model of migraine with aura . In another study, CSD directly activated trigeminovascular nociceptors without perivascular meningeal inflammation (the dura mater was not examined) .
If the carotid artery is occluded ipsilateral to the side of migraine headache then two-thirds will experience relief  indicating that cranial arteries are involved in migraine pain. The co-morbidities of migraine with aura and stroke, ischemic heart disease, and cervical arterial dissection [47–53] indicate a vascular or systemic component in migraine. The possible increased release of CGRP [23, 24, 54] in the external jugular vein is probably due to CGRP released locally from perivascular nerves. The small possible “infarcts” observed with MRI in the posterior cerebral circulation  indicate a vascular genesis. Brachial artery diameter (mean 4.82 vs. 5.39 mm) and compliance (mean 0.30 vs. 0.37 mm2/kPa) were decreased in migraine patients compared with controls . Carotid arterial wall properties were similar between groups . The CTf(a) was 1.0 and the verisimilitude was 0.
Does aura trigger the headache in migraine attacks?
The relationship between aura and headache in migraine with aura has been questioned . Some clinical evidence for a relationship exists. Thus, 35 (92%, 95 CI: 79–98%) out of 38 patients in whom both aura and headache were unilateral, felt that the headache and the aura were contralateral to each other; i.e. the headache was perceived over the affected hemisphere . Aura and headache were perceived as ipsilateral only in 3 patients. Notably, the results were obtained with prospective-symptom recording. As much as 19 patients had bilateral headache and could not provide evidence on whether or not aura triggers headache .
Experimentally, CSD activates trigeminal afferents and evokes a series of cortical meningeal and brain stem events . Several other animal studies showed that CSD can cause activation of the brain stem [59–61]. CSD activates matrix metalloproteinases, which open the blood–brain barrier . In one study, activation of trigeminovascular nociceptors by CSD occurred without perivascular inflammation . Neurogenic inflammation is, however, unlikely to be involved in migraine pain or in the link between aura and headache. Overall the CTv(a) is 1.0.
A clinical argument against aura as a migraine trigger is that most migraineurs never experience aura [29, 63], but the headache phase is, in principle, the same in migraine with or without aura . Additionally, there are well-documented cases of headache ipsilateral to aura . Patients with aura, but no headache are not uncommon [64, 65], challenging [57, 63] the notion that aura causes headache. Aura does not necessarily precede headache .
Experimental evidence against aura as a trigger of migraine pain comes from two studies in which there was no activation or sensitization of second-order neurons in TNC by CSD [66, 67]. The CTf(a) is 0.5.
I believe aura is likely to trigger a migraine attack, and the verisimilitude is +0.5.
Is brain stem activation measured with PET present during migraine attacks?
In three PET studies, brain stem activation was observed [4, 33, 34]. This activation persisted after treatment with sumatriptan [4, 33, 34]. Therefore, in all PET studies conducted so far, brain stem activation was found and the CTv(a) is 1.0. However, there is an unexplained inconsistency concerning the lateralization of activation and pain. In one study, PET activation was ipsilateral to pain , whereas it was contralateral [33, 34] or bilateral  to pain in others. The CTf(a) is 0.25. Brain stem activation during migraine is probable. However, lateralization is doubtful, making the pathophysiological implications unclear and the final verisimilitude is +0.75.
Is regional cerebral blood flow (rCBF) normal during attacks of migraine without aura?
rCBF, measured with SPECT, was normal before and during 8 wine-induced migraines without aura attacks . In two PET studies in migraine without aura attacks in either spontaneous (n = 9)  or GTN-induced (n = 24)  attacks, there was no occipital hypoperfusion. During spontaneous migraine attacks with a duration of 1–11 h, perfusion-weighted imaging reveals normal hemodynamic (n = 13) . The CTv(a) is judged to be 1.0.
rCBF during spontaneous/induced migraine without aura attacks were investigated with SPECT (n = 35)  and 74% of patients displayed an unilateral hypoperfusion, mainly in the occipital region. In one PET study, there was generally no change in rCBF, but analysis of individual data showed patchy hypoperfusion in the temporo/occipital region in 4 patients with migraine without aura . Global CBF was slightly, but significantly reduced in migraine without aura attacks compared with outside attacks (n = 9), 53 versus 60 ml/min/100 g, respectively . Occipital hypoperfusion was observed in another PET investigation in established attacks without aura (n = 6) . Spreading oligemia was observed with PET in one case . The resulting CTf(a) is most likely 1.0. Thus, no firm conclusion concerning rCBF in migraine without aura can presently be drawn and the verisimilitude is 0.
Is NO involved in migraine pathophysiology?
Glyceryl trinitrate induced migraine without aura with a latency of some hours in migraine sufferers, with and without aura, in 11 studies [2, 22, 75–83]. A double-blind, placebo-controlled design was used in two investigations [22, 78]. The NOS inhibitor, L-NMMA effectively treated migraine attacks . The CTv(a) is 1.0.
However, the two iNOS inhibitors GW274150 and GW273629 were ineffective in treating migraine attacks in one placebo-controlled study (n = 126)  and in an open-label pharmacokinetic study . Additionally, GW274150 was ineffective in a double-blind, placebo-controlled study as a prophylactic agent for migraine (n = 430) . Since other NOS isoforms (nNOS and eNOS) may be involved in the effect of NO , the CTf(a) is 0.25.
NO is most likely involved in the pathophysiology of migraine with a verisimilitude of +0.75.
Is neurogenic inflammation (NI) involved in the headache aspect of migraine?
If dural NI is involved in migraine, as proposed by Markowitz et al. , NI inhibitors would be predicted to be effective in migraine. This is true to some extent because ergot alkaloids and triptan inhibit NI [90, 91]. These drugs are, however, not specific NI inhibitors [92, 93]; however, endothelin and NK-1 receptor antagonists effectively inhibit NI in animal studies [94, 95]. The CTv(a) is 0.5.
Alternatively, several randomized clinical trials show no effect of substance P, neurokinin-1 antagonists [96–98], neurosteroid ganaxolone , endothelin antagonists , or the specific NI blockers CP122,288 and 4991w93 [101, 102] in the acute treatment of migraine. The CTf(a) is 1.0.
Is aura common in cluster headache attacks?
The next subject is theoretically important. If aura is not only linked to migraine with aura, but also with other primary headaches, such as cluster headaches, aura and migraine could be caused by two different mechanisms [57, 103]. In a recent paper , aura was described as being common in cluster headaches, with 23% of cluster headache patients in the study experiencing aura. Similarly, aura was reported in 28% of cluster headache patients in a series of 76 patients . In two earlier studies, aura was reported in 4  and 13% , respectively, of cluster headache patients. In 1972, Graham mentioned that brief episodes of scintillating rarely, but occasionally occur before cluster headache attacks . The CTv(a) for aura being common in cluster headache is thus 0.5.
Dr. Karl Ekbom from Stockholm, Sweden, an expert in cluster headache [108, 109] and migraine with aura , was asked his opinion. In a series of 554 cluster headache patients, there were no cases of aura in connection with cluster headache attacks . The CTf(a) is 1.0.
Aura is, therefore, likely to be rare in cluster headache patients, and the verisimilitude is −0.5.
Hypothalamic activation is specific for cluster headache and other trigeminal autonomic cephalalgias
Functional PET imaging shed light on the genesis of migraine and cluster headache by repeatedly documenting activation in the midbrain and pons during migraine, and in the hypothalamus during cluster headache. Two PET investigations found activation in the posterior hypothalamus during nitroglycerin-induced cluster headache attacks [112, 113]. Voxel-based morphometry with MRI found changes in the same region . Furthermore, with 1H-MR spectroscopy, hypothalamic-N-acetyl aspartate/creatinine was reduced in patients with cluster headache versus controls . In two patients with SUNCT, hypothalamic activation was observed with functional MRI [116, 117]. In paroxysmal hemicrania, hypothalamic activation was found with PET . In hemicrania continua, with a phenotype in between cluster headache and migraine, activation was observed both in the hypothalamus and in the brain stem .
In migraine without aura, hypothalamic activation was not found in two PET studies (n = 33) [4, 33]. Hypothalamic activation concurrent with brain stem activation was observed in one PET study in migraine without aura attacks (n = 7) [34, 73]. These activations persisted after successful treatment with sumatriptan [34, 73].
In this case, the Popper falsification rule  seems appropriate. Hypothalamic activation is not specific to cluster headache because it was observed in migraine without aura in a study with appropriate PET techniques .
Current migraine-mechanism theories vary from the notion that the migraine attack “consists of an abnormal perception of otherwise normal circumstances, such as pain without evidence of primary nociceptive activation”  to “migraine may be a local manifestation of a systematic vascular abnormality rather than a primary cerebral phenomenon”  or to “migraine is a neurovascular disorder” .
Popper’s verisimilitude calculation does not resolve problems always. Potentially, both the CTv(a) and CTf(a) can be 1.0 with a resulting verisimilitude of 0. Sometimes, one must fall back to the Popper falsification method, where negative facts that can falsify the hypothesis are the main stay. Migraine data are often not validated well enough to allow clear-cut conclusions. Particularly, confirmatory studies using the same methodology are often lacking.
In areas like migraine research, which is often descriptive, many cases of contradictory data exist because of both biological variability per se and different methods of measuring the biological signal.
No grand unifying theory exists in migraine research that can be falsified by itself or by its predictions , leaving only isolated relevant problems of basic and clinical migraine research for testing.
When evaluating the problems, we often used a mixture of facts from both kinds of research. Verisimilitude determinations can supplement the usual pros and cons by forcing judgement of the evidence for hypothesis a when assigning values to CTv(a) and CTf(a) . According to Popper, Vs(a) calculation is an objective method for judging a scientific theory or the predictions derived from a theory .
Verisimilitude measures the best correspondence with facts and should not be confused with probability . One can apply the simple verisimilitude formula to any field one knows well. Notably, verisimilitude calculations should not be applied to quantitative migraine treatment trials when a systematic review or meta-analysis is more appropriate [10–13].
Despite efforts at objectivity, some subjectivity remains in assigning values to Ct(a) and Ctf(a). Some may disagree with my calculations, but anyone can easily assign alternative Ct(a) and Cf(a) values and calculate verisimilitude for themselves.
Among the 10 cases judged by verisimilitude calculations, there were two −0.5 (unlikely), four 0 (undecided), one +0.25 (probably likely), one +0.5 (likely), and one +0.75 (most likely) (Table 1). For one item, the falsification ad modum Popper  was found to be more suitable. There was no −1.0 (very unlikely), probably because there is always some historical or recent evidence for the hypothesis tested [89–91, 104, 105]. The −0.5 depend on the formulation of the question. In four cases, we could not decide whether the theory was true or false because the evidence for and against it was of equal weight.
The verisimilitude approach is not problem-free. To illustrate, I discuss two problems in detail: migraine as a pure CNS disorder, possible aura in cluster headache, and cortical spreading depression (CSD).
The theory that migraine is a dysfunction of the sensory modulatory network  can be re-formulated as migraine is a pure human brain disease. Many good arguments exist for both sides and the CTv(a) and CTf(a) will still be 1.0 with the facts used in my analysis (Table 1), and verisimilitude will be 0. However, when using my prerogative as author and using our “natural instincts” (see vignette) combined with Popper’s falsification theory , I believe that the verisimilitude should be negative.
Thus, the theory that migraine is a brain disease would predict that there is no non-brain disorder associated with it. The main falsifying argument of this prediction is the cardiovascular comorbidity associated with migraine . For example, there is an association between cervical arterial dissection and migraine, mainly migraine with aura [52, 53]. Additionally, migraine, particularly migraine with aura, is a risk factor for ischemic stroke [47, 56]. The arteries of the systemic circulation were also investigated [56, 120, 122]. Migraineurs with recent onset (<6 years) had decreased brachial arterial diameters and compliances . Decreased flow-mediated dilatation of the brachial artery was also found in two other studies in migraineurs [120, 122].
Furthermore, some genetic arteriopathies are associated with migraine [123, 124] and in CADASIL, where the notch-3 gene appears to be expressed exclusively in vascular smooth muscles within adult brain . rCBF changes during migraine were similar in one case to migraine with aura [6, 126].
Circulating endothelial progenitor cell numbers and functions (i.e. endothelial repair markers) , are reduced, especially in migraine with aura patients . In two studies [48, 129], the von Willebrand factor, a plasma marker of endothelial dysfunction, was increased in migraine. Thus, there is good evidence that migraine is associated with endothelial dysfunction, and could be the underlying link between migraine and cardiovascular risk [49, 128].
I believe that the arguments against the predictions of the neuronal theory of migraine falsify this theory . Migraine is unlikely to be a brain-only disease. Another argument against the neuronal theory is that no other part of the human body experiences pain without nociceptive input except thalamic pain and other neuronal lesions with sensory signs . In migraine, there can be allodynia, but no sensory signs . I believe that, in addition to a clear CNS component, there is also a peripheral component in the headache phase. Regarding the source of pain, Goadsby recently stated “The pain process is likely to be a combination of direct factors, i.e. activation of the nociceptors of pain-producing intracranial structures, in concert with a reduction in the normal functioning of the endogenous pain control pathways that normally gate that pain” . I agree that there is both a peripheral and central aspect of migraine headache. Because of the pulsating pain in migraine, I believe vascular nociception most likely  even though the verisimilitude of large arterial vasodilation during migraine was zero.
The question of aura in cluster headache
Four recent papers report prevalences of 4 to 28% for aura in cluster headache [103–106]. One may wonder how such a frequent and characteristic phenomenon went unrecognized by Baylor Horton, who described histaminic cephalalgia in 1938 (n = 181) . Horton later in 1956 reported seeing 1,176 patients (1,023 men and 153 women) with histaminic cephalalgia . Aura is not mentioned by Kudrow whose book from 1980 included 495 patients . However, the cluster headache expert John R. Graham wrote “Now to our surprise we were able to establish that in 20 cluster headache patients brief episodes of scintillating scotoma rarely, but occasionally, did precede the cluster headache attacks” . However, there are inconsistencies in the prevalences reported. The highest reported prevalence is 28% (n = 76)  and the lowest is 4% (n = 101) , a difference of 24% (95% CI 13–34%, P < 0.0001, Fisher’s exact test). The difference between the 23  and 4%  prevalence is 19% (95% CI 13–26%, P < 0.0001). Also, prevalence was significantly different between the two largest studies: 23 (n = 246)  versus 13% (n = 230) , a difference of 10% (95% CI 2–16%, P = 0.01). These differences demonstrate that the method of registering “so-called aura” must have varied considerably.
In contrast, no reports of aura in cluster headache were reported in a large series of 554 cluster headache patients from one Swedish center . Karl Ekbom, who has a special interest in aura , personally interviewed 427 patients, and observed and questioned about 100 of them during spontaneous or provoked cluster headache attacks .
Confronted with these incomparable data, it is a matter of belief or trust. Both sets of contradictory data cannot be an approximation of the truth and I calculated the verisimilitude to be −0.5. In my opinion, aura must be rare among cluster headache patients.
In conclusion, I believe verisimilitude calculations are suitable for many migraine and cluster headache mechanism problems. Contradictory data concerning a specific problem are common and a verisimilitude calculation enforces a qualitative judgement of the data. Sometimes, the resulting verisimilitude is zero, but both, CTv(a) and CTf(a), cannot be an approximation of the truth. In some cases, further investigation is needed or a clearer hypothesis should be formulated, and appropriate investigations aimed at falsifying the thesis  should be performed. Finally, positive evidence is never conclusive; but neither is negative evidence, nor would it be a good idea to pretend that it was .
Lipton P (2005) The Medawar Lecture 2004 the truth about science. Philos Trans R Soc Lond B Biol Sci 360:1259–1269, 16147521, 10.1098/rstb.2005.1660
Thomsen LL, Kruuse C, Iversen HK, Olesen J (1994) A nitric oxide donor (nitroglycerin) induces genuine migraine attacks. Eur J Neurol 1:73–80
Olesen J (2008) The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther 120:157–171, 1:CAS:528:DC%2BD1cXht1Knsb3I, 18789357, 10.1016/j.pharmthera.2008.08.003
Afridi SK, Matharu MS, Lee L, Kaube H, Friston KJ, Frackowick RS et al (2005) A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 128:932–939, 1:STN:280:DC%2BD2M7lsV2jug%3D%3D, 15705611, 10.1093/brain/awh416
Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 22:54–61, 1:STN:280:DC%2BD383ltlGrtA%3D%3D, 11993614, 10.1046/j.1468-2982.2002.00310.x
Olesen J, Iversen HK, Thomsen LL (1993) Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport 4:1027–1030, 1:CAS:528:DyaK2cXhs1SlsLY%3D, 8241457, 10.1097/00001756-199308000-00008
Goadsby PJ, Charbit AR, Andreou AP, Akerman S, Holland PR (2009) Neurobiology of migraine. Neuroscience 161:327–341, 1:CAS:528:DC%2BD1MXms1WjsLo%3D, 19303917, 10.1016/j.neuroscience.2009.03.019
Popper KR (1959) The logic of scientific discovery. Routledge, London
International Headache Society Clinical Trial Subcommittee (2000) Guidelines for controlled trials of drugs in migraine, vol 20, 2nd edn. Cephalalgia, pp 765–786
Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259–1287, 1:CAS:528:DC%2BD3MXktFarsA%3D%3D, 11152011, 10.2165/00003495-200060060-00003
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT1B/1B agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358:1668–1675, 1:CAS:528:DC%2BD3MXos1ajsro%3D, 11728541, 10.1016/S0140-6736(01)06711-3
Linde K, Rossnagel K (2004) Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2:CD003225
Sultan A, McQuay HJ, Moore RA, Derry S (2009) Single dose oral flurbiprofen for acute postoperative pain in adults. Cochrane Database Syst Rev (3):CD007358
Popper KR (2003) Conjectures and refutations. The growth of scientific knowledge. Routledge, London
Graham JR, Wolff HG (1938) Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 39:737–763, 1:CAS:528:DyaA1cXkvVCjtQ%3D%3D
Wolff HG (1963) Headache and other head pain, 2nd edn. Oxford University Press, New York
Friberg L, Olesen J, Iversen HK, Sperling B (1991) Migraine pain associated with middle cerebral dilatation: reversal by sumatriptan. Lancet 336:13–17, 10.1016/0140-6736(91)90005-A
Thomsen LL, Iversen HK, Olesen J (1995) Cerebral blood flow velocities are reduced during attacks of unilateral migraine without aura. Cephalalgia 15:109–116, 1:STN:280:DyaK2MzmvVKruw%3D%3D, 7641244, 10.1046/j.1468-2982.1995.015002109.x
Totaro R, De matteis G, Marini C, Balassarre M, Carolei A (1997) Sumatriptan and cerebral blood flow velocity changes during migraine attacks. Headache 37:635–639, 1:STN:280:DyaK1c7gt1Sksw%3D%3D, 9439084, 10.1046/j.1526-4610.1997.3710635.x
Zwetsloot CP, Caebeke J, Odink J, Ferrari MD (1991) Vascular reactivity during migraine attacks: a transcranial Doppler study. Headache 31:593–595, 1:STN:280:DyaK387ivFWltg%3D%3D, 1774174, 10.1111/j.1526-4610.1991.hed3109593.x
Zwetsloot CP, Caebeke J, Ferrari MD (1993) Lack of asymmetry of middle cerebral artery blood velocities in unilateral migraine. Stroke 24:1335–1338, 1:STN:280:DyaK3szmvFymsw%3D%3D, 8362427
Schoonman GG, van der Grond J, Kortman C, van der Geest RJ, Terwindt GM, Ferrari MD (2008) Migraine headache is no associated with cerebral or meningeal vasodilation—a 3T magnetic resonance angiographic study. Brain 131:2192–2200, 1:STN:280:DC%2BD1cvps1WltQ%3D%3D, 18502781, 10.1093/brain/awn094
Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183–187, 1:STN:280:DyaK3M%2FisVSktQ%3D%3D, 1699472, 10.1002/ana.410280213
Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and in cats. Ann Neurol 33:48–56, 1:STN:280:DyaK3s3mtlGqsw%3D%3D, 8388188, 10.1002/ana.410330109
Vause CV, Durham PL (2009) Calcitonin gene-related peptide differentially regulates gene and protein expression in trigeminal neurons and glia cells: findings from array analysis. Cephalalgia 29(suppl 1):116–117
Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J (2005) No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 58:561–563, 1:CAS:528:DC%2BD2MXhtFGrsL7O, 16178016, 10.1002/ana.20605
Tfelt-Hansen P (2010) Calcitonin gene-related peptide in external jugular vein during migraine and cluster headache. Is it increased? In: Olesen J (ed) Role of calcitonin gene-related peptide (CGRP) and adrenomedullin (AM) in migraine. Frontiers in headache research, vol 17. Oxford University Press (in press)
Kelman L (2004) The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache 44:865–872, 15447695, 10.1111/j.1526-4610.2004.04168.x
Olesen J, Goadsby PJ, Ramadan N, Tfelt-Hansen P, Welch KMA (eds) (2006) The headaches, 3rd edn. Lippincott Williams and Wilkins, Philadelphia, pp 1–1169
Olesen J, Larsen B, Lauritzen M (1981) Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 9:344–352, 1:STN:280:DyaL3M7ot1yhsg%3D%3D, 6784664, 10.1002/ana.410090406
Lauritzen M, Olsen TS, Lassen NA, Paulson OB (1983) Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann Neurol 13:633–641, 1:STN:280:DyaL3s3otFGitQ%3D%3D, 6881926, 10.1002/ana.410130609
Hajdikhani N, Sanchez del Rio M, Wu O, Schwartz D, Bakker D, Fischl B et al (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 08:4687–4692
Weiller C, May A, Limroth V, Jüpter M, Kaube H, Schayck RV et al (1995) Brain stem activation in spontaneous human migraine attacks. Nat Med 1:658–660, 1:CAS:528:DyaK2MXms1Kgsbs%3D, 7585147, 10.1038/nm0795-658
Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G (2007) Hypothalamic activation in spontaneous migraine attacks. Headache 47:1418–1425, 18052951
Haas DC, Kent PF, Friedman DI (1993) Headache caused by a single lesion of multiple sclerosis in the periaqueductal gray area. Headache 33:452–455, 1:STN:280:DyaK2c%2Fos1eitA%3D%3D, 8262789, 10.1111/j.1526-4610.1993.hed3308452.x
Afridi S, Goadsby PJ (2003) New onset of migraine with a brain stem cavernoma. J Neurol Neurosurg Psychiatry 74:680–682, 1:STN:280:DC%2BD3s7otFOisA%3D%3D, 12700321, 10.1136/jnnp.74.5.680
SchoenenJ Maetens, de Noordhout A, Timsit-Berthier M, Timsit M (1986) Contingent negative variation and efficacy of beta-blocking agents in migraine. Cephalalgia 6:229–233, 10.1046/j.1468-2982.1986.0604229.x
Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA (2006) Suppression of cortical depression in migraine prophylaxis. Ann Neurol 59:652–661, 1:CAS:528:DC%2BD28XktFWjsrY%3D, 16450381, 10.1002/ana.20778
Storer RJ, Goadsby PJ (1997) Microiontophoretic application of serotonin (5HT) 1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 120:2171–2177, 9448572, 10.1093/brain/120.12.2171
Storer RJ, Goadsby PJ (2004) Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia 24:1049–1056, 1:STN:280:DC%2BD2crptlantA%3D%3D, 15566419, 10.1111/j.1468-2982.2004.00767.x
Kaube H, Hoskin KL, Goadsby PJ (1993) Inhibition by sumatriptan of central trigeminal neurons only after blood-brain barrier disruption. Br J Pharmacol 109:788–792, 1:CAS:528:DyaK3sXltlWnsbw%3D, 8395298
Hoskin KL, Bulmer DC, Goadsby PJ (1999) Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci Lett 266:173–176, 1:CAS:528:DyaK1MXjsVSgtLg%3D, 10465701, 10.1016/S0304-3940(99)00281-5
Goadsby PJ, Hoskin KL (1999) Differential effects of low dose CP122, 288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat. Pain 82:15–22, 1:CAS:528:DyaK1MXksV2qur8%3D, 10422655, 10.1016/S0304-3959(99)00025-1
Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA (2002) Intrinsic brain activity triggers trigeminal afferents in a migraine model. Nat Med 8:136–142, 1:CAS:528:DC%2BD38Xht1equrc%3D, 11821897, 10.1038/nm0202-136
Maneesri S, Patamanon J, Patumja S, Srkiatknachora A (2004) Cortical spreading depression, meningeal inflammation and trigeminal nociception. Neuroreport 15:1623–1637, 15232295, 10.1097/01.wnr.0000134989.89428.3b
Drummond PD, Lance JW (1983) Extracranial vascular changes and the source of pain in migraine headache. Ann Neurol 13:32–37, 1:STN:280:DyaL3s7ltFegug%3D%3D, 6830162, 10.1002/ana.410130108
Bousser M-G, Welch KMA (2005) Relation between migraine and stroke. Lancet Neurol 4:533–542, 16109360, 10.1016/S1474-4422(05)70164-2
Tietjen GE (2009) Migraine a systemic vasculopathy. Cephalalgia 29:987–996, 1:STN:280:DC%2BD1MrmtlOhug%3D%3D, 19689607, 10.1111/j.1468-2982.2009.01937.x
Stam AH, Haan J, van den Maagdenberg AMJM, Ferrari MD, Terwindt GM (2009) Migraine and genetic and acquired vasculopathies. Cephalalgia 29:1006–1017, 1:STN:280:DC%2BD1MrmtlOgsw%3D%3D, 19689610, 10.1111/j.1468-2982.2009.01940.x
Bigal ME, Santanello NC, Buse DC, Kurth T, Golden WM, Robbins MS, Lipton RB (2009) Migraine with and without aura are associated with cardiovascular disease. The American migraine prevalence and prevention study. Cephalalgia 29(Suppl 1):8
Artto VA, Meyso TM, Metso AJ, Putaala J, Haapaniemi E, Färkkilä M et al (2009) Migraine with aura is a risk factor for cervical artery dissection; a case control study. Cephalalgia 29(Suppl 1):114
Rubenstein SM, Peerdeman SM, van Tulder MW, Riphagen I, Haldeman S (2005) A systematic review of the risk factors for cervical artery dissection. Stroke 36:1575–1580, 10.1161/01.STR.0000169919.73219.30
Tzourio C, Benslamia L, Guillon B, Aïdi S, Bertrand M, Berthet K et al (2002) Migraine and the risk of cervical arterial dissection: a case-controlled study. Neurology 59:435–437, 1:STN:280:DC%2BD38vitV2qtA%3D%3D, 12177380
Tfelt-Hansen P, Le H (2009) Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache attacks? A review. J Headache Pain 10:137–143, 1:CAS:528:DC%2BD1MXls1Oksb8%3D, 19330286, 10.1007/s10194-009-0112-8
Kruit MC, Launer LJ, Ferrari MD, van Buchem MA (2005) Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain 128:2068–2077, 16006538, 10.1093/brain/awh542
Vanmolkot FH, Van Bortel LM, de Hoon JN (2007) Altered arterial function in migraine of recent onset. Neurology 68:1563–1570, 17460157, 10.1212/01.wnl.0000260964.28393.ed
Goadsby PJ (2001) Migraine, aura, and cortical spreading depression: why are we still talking about it? Ann Neurol 49:4–6, 1:STN:280:DC%2BD3M7gslKktw%3D%3D, 11198295, 10.1002/1531-8249(200101)49:1<4::AID-ANA3>3.0.CO;2-W
Olesen J, Friberg L, Olsen TS, Iversen HK, Lassen NA, Andersen AR et al (1990) Timing and topography of cerebral blood flow, aura and headache during migraine attacks. Ann Neurol 28:791–798, 1:STN:280:DyaK3M7js1Wlsg%3D%3D, 2285266, 10.1002/ana.410280610
Moskowitz MA, Nozahi K, Kraig RP (1993) Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 13:1167–1177, 1:CAS:528:DyaK3sXhvVCisb0%3D, 8382735
Read SJ, Hirst WD, Upton N, Parsons A (2001) Cortical spreading depression produces increased cGMP levels in cortex and brain stem that is inhibited by tonabersat (SB-220453) but not sumatriptan. Brain Res 891:69–77, 1:CAS:528:DC%2BD3MXnsVGhsw%3D%3D, 11164810, 10.1016/S0006-8993(00)03191-7
Kunkler PE, Kraig RP (2003) Hippocampal spreading depression bilaterally activates the caudal trigeminal nucleus in rodents. Hippocampus 13:835–844, 14620879, 10.1002/hipo.10139
Gursoy-Ozdemir Y, Qui J, Matsuoka N, Bolay H, Bernpohl D, Jin H et al (2004) Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 113:1447–1455
Messlinger K (2009) Migraine; where and how does the pain originate? Exp Brain Res 196:179–193, 19288089, 10.1007/s00221-009-1756-y
Russell MB, Olesen J (1996) A nosographic analysis of migraine aura in a general population. Brain 119:335–361
Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J (2009) Effects of tonabersat on migraine with aura; a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol 8:723–728, 10.1016/S1474-4422(09)70135-8, 1:CAS:528:DC%2BD1MXpvFentL0%3D
Ebersberger A, Schaible HG, Averbech B, Richter F (2001) Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann Neurol 49:7–13, 1:STN:280:DC%2BD3M7gslKkuw%3D%3D, 11198299, 10.1002/1531-8249(200101)49:1<7::AID-ANA4>3.0.CO;2-K
Ingvardsen BK, Lauersen H, Olsen UB, Hansen AJ (1997) Possible mechanism of c-fos expression in the trigeminal nucleus caudalis following cortical spreading depression Pain 72:407–415, 1:CAS:528:DyaK2sXlslersb0%3D
Olesen J, Tfelt-Hansen P, Henriksen L, Larsen B (1981) Common migraine may not be initiated by cerebral ischemia. Lancet II:438-440
Sanchez del Rio M, Bakker D, Wu O, Agosti R, Mitsikostas PD, Ostergaard L et al (1999) Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia 19:701–707, 1:STN:280:DC%2BD3c%2FjsleisQ%3D%3D, 10570723, 10.1046/j.1468-2982.1999.019008701.x
De Benedittis G, Ferrari Da Passano C, Granata G, Lorenzetti A (1999) CBF changes during headache-free periods and spontaneous/induced attacks in migraine with and without aura: a TCD and SPECT comparison study. J Neurosurg Sci 43:141–146, 10735768
Andersson JL, Muhr C, Liljen A, Valind S, Lundberg PÅ, Långström B (1997) Regional cerebral blood flow and oxygen metabolism during migraine with and without aura. Cephalalgia 27:570–579, 10.1046/j.1468-2982.1997.1705570.x
Bednarczyk EM, Remler B, Weikart C, Nelson AD, Reed RC (1998) Global cerebral blood flow, blood volume, and oxygen metabolism in patients with migraine headache. Neurology 50:1736–1740, 1:STN:280:DyaK1c3psFCktA%3D%3D, 9633719
Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G (2008) Posterior cerebral hypoperfusion in migraine without aura. Cephalalgia 28:856–862, 1:STN:280:DC%2BD1cvnslaisA%3D%3D, 18513260, 10.1111/j.1468-2982.2008.01623.x
Woods RP, Iacoboni M, Mazziotta JC (1994) Brief report: bilateral spreading hypoperfusion during spontaneous migraine headache. N Eng J Med 331:1689–1692, 1:STN:280:DyaK2M%2FlvFehug%3D%3D, 10.1056/NEJM199412223312505
Peters GA (1953) Migraine: diagnosis and treatment with emphasis on the migraine-tension headache, provocative tests and use of rectal suppositories. Proc Staff Meet Mayo Clin 28:673–686, 1:STN:280:DyaG2c%2Fkt1Smtg%3D%3D, 13121092
Sicuteri F, del Bene ED, Poggioni M, Bonnazzi A (1987) Unmasking latent dysnociception in healthy subjects. Headache 27:180–185, 1:STN:280:DyaL2s3kvFOmsQ%3D%3D, 3110103, 10.1111/j.1526-4610.1987.hed2704180.x
Tfelt-Hansen P, Daugaard D, Lassen LH, Iversen HK, Olesen J (2009) Prednisolone reduces nitric oxide-induced migraine. Eur J Neurol 16:1106–1111, 1:STN:280:DC%2BD1MnjslSmug%3D%3D, 19614965, 10.1111/j.1468-1331.2009.02654.x
Thomsen LL, Iversen HK, Brinck TA, Olesen J (1993) Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers. Cephalalgia 13:395–399, 1:STN:280:DyaK2c7kslCrtQ%3D%3D, 7906202, 10.1046/j.1468-2982.1993.1306395.x
Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J et al (2003) NO-induced migraine attacks: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 106:461–470, 1:CAS:528:DC%2BD3sXptlyjs7k%3D, 14659530, 10.1016/j.pain.2003.09.008
Juhasz G, Zsombok T, Jakab B, Nemeth J, Szoksanyl J, Bagny G (2005) Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attacks. Cephalalgia 25:179–183, 1:STN:280:DC%2BD2M%2FmtVyqsA%3D%3D, 15689192, 10.1111/j.1468-2982.2005.00836.x
Juhasz G, Zsombok T, Gonda X, Nagyne N, Modosne E, Bagdy G (2007) Effects of autogenic training on nitroglycerin-induced headache. Headache 47:371–383, 17371354
Christiansen I, Thomsen LL, Daugaard D, Ulrich V, Olesen J (1999) Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia 19:660–667, 1:STN:280:DyaK1Mvlt1aqsw%3D%3D, 10524660, 10.1046/j.1468-2982.1999.019007660.x
Christiansen I, Daugaard D, Lykke Thomsen L, Olesen J (2000) Glyceryl trinitrate induced headache in migraineurs—relation to attack frequency. Eur J Neurol 7:405–411, 1:STN:280:DC%2BD3cvls1Cqsw%3D%3D, 10971600, 10.1046/j.1468-1331.2000.00094.x
Lassen LH, Ashina M, Christiansen I, Ulrich V, Grover R, Donaldson J et al (1998) Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 18:27–32, 1:STN:280:DyaK1c3mtl2htQ%3D%3D, 9601621, 10.1046/j.1468-2982.1998.1801027.x
Palmer JE, Guillard FL, Laurijssens BE, Wentz AL, Dixon RM, Williams PM (2010) A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia (in press)
Van der Schueren BJ, Lunnon MW, Laurijssens BE, Guillard F, Palmer J, Van Hecken A et al (2009) Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in migraine? J Clin Pharmacol 49:281–290, 19246728, 10.1177/0091270008329548, 1:CAS:528:DC%2BD1MXjslamtbo%3D
Hoye K, Laurijssens BE, Harnisch LO, Twormey CK, Dixon RM, Kirkham A et al (2009) Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for twelve weeks in the prophylactic treatment of migraine. Cephahalgia 29:132
Akerman S, Williamson DJ, Kaube H, Goadsby PJ (2002) Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol 130:62–68, 10.1038/sj.bjp.0704842, 1:CAS:528:DC%2BD38XmslClt7g%3D
Markowitz S, Saito K, Moskowitz MA (1987) Neurogenically mediated leakage of plasma protein occurs from blood vessels in the dura mater but not brain. J Neurosci 7:4129–4136, 1:CAS:528:DyaL1cXltlOktw%3D%3D, 3694267
Saito K, Markowitz S, Moskowitz MA (1988) Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol 24:732–737, 1:CAS:528:DyaL1MXovVGktg%3D%3D, 3207357, 10.1002/ana.410240607
Buzzi MG, Mokowitz MA (1991) Evidence for the 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 11:165–168, 1:STN:280:DyaK38%2Fns1CntA%3D%3D, 1660351, 10.1046/j.1468-2982.1991.1104165.x
Tfelt-Hansen P, Saxena PR (2006) Ergot alkaloids in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The Headaches, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 459–467
Saxena PR, Tfelt-Hansen P (2006) Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The Headaches, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 469–503
Brändli P, Löffler BM, Breu V, Osterwalder R, Maire JP, Clozel M (1996) Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 64:315–322, 8740609, 10.1016/0304-3959(95)00106-9
Phebus LA, Johnson KW, Stengel PW, Lobb KL, Nixon JA, Hipskind PA (1997) The non-peptide NK-1 receptor antagonists LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life Sci 60:1553–1561, 1:CAS:528:DyaK2sXitl2nurY%3D, 9126877, 10.1016/S0024-3205(97)00121-5
Connor HE, Bertin L, Gilles S, Beattie DT, Ward P, the GR295171 Clinical Study Group (1998) Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine. Cephalalgia 18:392
Diener HC (2003) RPR100893, a substande-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 23:183–185, 12662184, 10.1046/j.1468-2982.2003.00496.x
Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT (1997) Ineffectiveness of neurokinin-1 antagonist in acute treatment of migraine: a crossover study. Cephalalgia 17:785–790, 1:STN:280:DyaK1c%2FmtFelsg%3D%3D, 9399010, 10.1046/j.1468-2982.1997.1707785.x
Data J, Britch K, Westergaard N, Weihnuller F, Harris S, Swarz H, Silberstein S, Goldstein J, Ryan R, Saper J, Londborg P, Winner P, Klapper J (1998) A double-blind study of ganaxolone in the treatment of migraine headaches with and without aura in premenopausal females. Headache 38:380
May A, Gijsman HJ, Wallnoefer A, Jones R, Diener HC, Ferrari MD (1996) Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 67:375–378, 1:CAS:528:DyaK28XnsVCrtbw%3D, 8951932, 10.1016/0304-3959(96)03137-5
Roon K, Diener HC, Ellis P, Hettiarachchi J, Poole P, Christiansen I, Ferrari MD, Olesen J (1997) CP-122, 288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical studies. Cephalalgia 17:245
Earl NL, McDonald SA, Lowy Mt, 4991W93 Investigator Group (1999) Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine. Cephalalgia 19:357
Bahra A, May A, Goadsby PJ (2002) Cluster headache: a prospective clinical study with diagnostic implications. Neurology 58:354–361, 11839832
Schürks M, Kurth T, de Jesus J, Jonsic M, Rosskopf D, Diener HC (2006) Cluster headache: medical presentation, lifestyle factors, and medical treatment. Headache 46:1246–1254, 16942468, 10.1111/j.1526-4610.2006.00534.x
Wöber C, Knopf A (2009) Migrainous features in cluster headache. Cephalalgia 29(suppl 1):44 Abstract, Abstract
Silberstein SD, Niknam R, Rozen TD, Young WB (2000) Cluster headache with aura. Neurology 54:219–221, 1:STN:280:DC%2BD3c7gtVWjtQ%3D%3D, 10636152
Graham JR (1972) Cluster headache. Headache 11:175–185, 1:STN:280:DyaE38%2FosVWhsA%3D%3D, 5007729, 10.1111/j.1526-4610.1972.hed1104175.x
Ekbom K, Svensson DA, Träff H, Waldenlind E (2002) Age at onset and sex ratio in cluster headache: observation over three decades. Cephalalgia 22:94–100, 1:STN:280:DC%2BD383lsVyiuw%3D%3D, 11972575, 10.1046/j.1468-2982.2002.00318.x
Ekbom K, Svensson DA, Pedersen NL, Waldenlind E (2006) Life time prevalence and concordance risk of cluster headache in the Swedish twin population. Neurology 67:798–803, 16966540, 10.1212/01.wnl.0000233786.72356.3e
Ekbom K (1970) A clinical comparison of cluster headache and migraine. Acta Neurol Scand 46(Suppl 41):1–48
Ekbom K, Waldenlind E, Tfelt-Hansen P (2009) Cluster headache and aura. Headache 49:786–787, 19456891, 10.1111/j.1526-4610.2009.01417.x
May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ (1998) Hypothalamic activation in cluster headache. Lancet 352:275–278, 1:STN:280:DyaK1czlt1OitQ%3D%3D, 9690407, 10.1016/S0140-6736(98)02470-2
May A, Bahra A, Büchel C, Frackowiak RS, Goadsby PJ (2000) PET and MRA findings in cluster headache and MRA in experimental pain. Neurology 55:1328–1335, 1:STN:280:DC%2BD3M%2FlvFygtA%3D%3D, 11087776
May A, Ashenburner J, Büchel C, McGonicle DJ, Friston KJ, Frackowiak RS et al (1999) Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nat Med 5:836–838, 1:CAS:528:DyaK1MXksVCrur0%3D, 10395332, 10.1038/10561
Lodi R, Oieranggeli G, Tonon C, Cevoli S, Testa C, Bivona G et al (2006) Study of hypothalamic metabolism in cluster headache by proton MR spectroscopy. Neurology 66:1264–1266, 1:CAS:528:DC%2BD28XjtFOrtLg%3D, 16636250, 10.1212/01.wnl.0000208442.07548.71
May A, Bahra A, Büchel C, Turner R, Goadsby PJ (1999) Functional magnetic resonance imaging in spontaneous attacks of SUNCT: short-lasting unilateral neuralgiform headache with conjunctival injection and tearing. Ann Neurol 46:791794, 10.1002/1531-8249(199911)46:5<791::AID-ANA18>3.0.CO;2-8
Matharu MS, Cohen AS, Boes CJ, Goadsby PJ (2003) Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome: a review. Curr Pain Headache Rep 7:308–318, 12828881, 10.1007/s11916-003-0052-y
Matharu MS, Cohen AS, Frackowiak RS, Goadsby PJ (2006) Posterior hypothalamic activation in paroxysmal hemicrania. Ann Neurol 59:535–545, 16489610, 10.1002/ana.20763
Matharu MS, Cohen AS, MGGonigle DJ, Ward N, Frackowiak RS, Goadsby PJ (2004) Posterior hypothalamic and brainstem activation in hemicrania continua. Headache 44:747–761, 15330820, 10.1111/j.1526-4610.2004.04141.x
Yetkin E, Ozisik H, Ozcan C, Aksoy Y, Turban H (2007) increased dilator response to nitrate and decreased flow-mediated dilatation in migraineurs. Headache 47:104–110, 17355503
Villalon CM, Olesen J (2009) The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther 124:309–323, 1:CAS:528:DC%2BD1MXhsVKgs7fL, 19796656, 10.1016/j.pharmthera.2009.09.003
Yetkin E, Ozisik H, Ozcan C, Aksoy Y, Turban H (2006) Decreased endothelium-dependent vasodilatation in patients with migraine: a new aspect to vascular pathophysiology of migraine. Coron Artery Dis 17:29–33, 16374138, 10.1097/00019501-200602000-00005
Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser M-G (2009) CADASIL. Lancet Neurol 643–653
Dichgans M, Mayer M, Uttner I, Brüning R, Müller-Höcker J, Rungger G et al (1998) The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 44:731–739, 1:STN:280:DyaK1M%2FjsVagtQ%3D%3D, 9818928, 10.1002/ana.410440506
Moskowitz MA, Kurth T (2007) Blood vessels, migraine, and stroke. Stroke 38:3117–3118, 17962586, 10.1161/STROKEAHA.107.495770
Tfelt-Hansen P, Olesen J (2008) Delayed hyperperfusion following migraine with a prolonged aphasic aura in a patient with CADASIL. Cephalalgia 28:899–902, 1:STN:280:DC%2BD1cvnslCktQ%3D%3D, 18540869, 10.1111/j.1468-2982.2008.01626.x
Schwedt JJ (2009) Endothelial dysfunction in migraine. Cephalalgia 997–1002
Lee ST, Chu K, Jung KM, Kim DH, Choe VN, Kim JH et al (2008) Decreased number of endothelial progenitor cells in patients with migraine. Neurology 70:1510–1517, 18354079, 10.1212/01.wnl.0000294329.93565.94
Tiejten GE (2007) Migraine as a systemic disorder. Neurology 68:1555–1556, 10.1212/01.wnl.0000265415.18382.fb
Olesen J, Burstein R, Ashina M, Tfelt-Hansen P (2009) Origin of pain (nociception) in migraine. Lancet Neurol 8:679–690, 19539239, 10.1016/S1474-4422(09)70090-0
Horton BT, MacLean AR, WMcK Craig (1939) A new syndrome of vascular headache: results of treatment with histamine: preliminary report. Proc Staff Meet Mayo Clinic 14:257–260
Kudrow L (1980) Cluster headache. Mechanisms and management. Oxford University Press, New York
Horton BT (1956) Histaminic cephalalgia; differential diagnosis and treatment. Proc Staff Meet Mayo Clin 1:325–333
May A (2005) The role of imaging in the pathophysiology and diagnosis of headache. Current Opin Neurol 18:293–297, 10.1097/01.wco.0000169748.44782.af
Conflict of interest